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Summary: A model for drug interaction between amlodipine and simvastatin was developed using concen-
tration data obtained from a multiple-dose study consisting of single- and co-administration of amlodipine
and simvastatin conducted in healthy Koreans. Amlodipine concentrations were assumed to inﬂuence the
clearance of simvastatin and simvastatin acid, which as well as the oral bioavailability was allowed to vary
depending on genetic polymorphisms of metabolic enzymes. Covariate effects on drug concentrations were
also considered. The developed model yielded a 46% increase in simvastatin bioavailability and a 13%
decrease in simvastatin clearance when amlodipine 10mg was co-administered. When CYP3A4/5 poly-
morphisms were assessed by a mixture model, extensive metabolizers yielded a decrease in simvastatin
bioavailability of 81% and a decrease in simvastatin clearance by 4.6 times as compared to poor metabo-
lizers. Sixty percent of the usual dose was the optimal simvastatin dose that can minimize the interac-
tion with amlodipine 10mg. Age and weight had signiﬁcant effects on amlodipine concentrations. In
conclusion, this study has quantitatively described the pharmacokinetic interaction between simvastatin and
amlodipine using a modeling approach. Given that the two drugs are often prescribed together, the
developed model is expected to contribute to more efﬁcient and safer drug treatment when they are co-
administered.
Keywords: drug-drug interaction; simvastatin; amlodipine; metabolite; mixture model; population
anlyisis
Introduction
Pharmacokinetic drug interactions can occur when at least two
drugs are co-administered, typically increasing or decreasing the
concentration of the ﬁrst drug, and these altered concentrations can
cause an unexpected adverse drug reaction or therapeutic failure.1)
A notable metabolic enzyme system involved in drug interac-
tions is the cytochrome P450 oxidase family (CYP450), which,
when inhibited or induced by drug interactions, affects the plasma
concentrations of a drug. Competitive inhibition is a form of
enzyme inhibition whereby binding of an inhibitor to the active
site on the enzyme prevents binding of the substrate and vice
versa.2) When two or more drugs that use a common enzymatic
system are administered concomitantly, they can interact with each
other in a competitive manner.
Simvastatin is a hydroxyl-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitor used to control hypercholesterolemia.3)
Simvastatin lowers cholesterol levels in the blood by blocking an
enzyme system that creates cholesterol. Simvastatin is metabolized
through a complex system including acid/lactone interconversion
via various pathways. Simvastatin, which is an inactive lactone,
is converted to its active form, simvastatin acid, by esterases,
paraoxonases and non-enzymatic hydrolysis. Simvastatin acid is
converted back to simvastatin via the acyl glucuronide intermediate
and the CoASH-dependent pathway.3) Metabolic elimination of
both simvastatin and simvastatin acid occur via cytochrome P450
3A4/5 (CYP3A4/5). It has been reported that the CYP3A5 genetic
polymorphism inﬂuences the pharmacokinetics of simvastatin.4)
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Amlodipine is a long-acting calcium channel blocker [di-
hydropyridine (DHP) class] used as an anti-hypertensive and in the
treatment of angina.5,6) In hypertension, like other calcium channel
blockers, amlodipine reduces blood pressure by relaxing the
smooth muscle in the arterial wall and decreasing total peripheral
resistance and in angina it increases blood ﬂow to the heart muscle.
In reality, simvastatin is often co-administered with amlodipine
for the treatment of hyperlipidemia accompanied by hypertension.
However, CYP3A is a known major enzyme subfamily respon-
sible for the metabolism of amlodipine as well as simvastatin and
simvastatin acid.3,7) It has been reported that the concentration
of simvastatin increases when co-administered with amlodipine,
which can competitively inhibit the metabolic activity of CYP3A4/
5. On the other hand, it is known that amlodipine concentration
is not inﬂuenced by simvastatin when the two drugs are co-
administered.8)
Thus, when simvastatin and amlodipine are co-administered,
amlodipine can compete with simvastatin in the same metabolic
pathway, altering simvastatin metabolism and consequently raising
the risk of an adverse drug reaction due to increased blood con-
centrations of simvastatin. To date, however, population pharmaco-
kinetic analyses of drug-drug interactions between simvastatin and
amlodipine have not been conducted.
The objectives of this study were (i) to develop a population
model to describe the pharmacokinetics of simvastatin, simvastatin
acid, amlodipine, and their drug interactions from data obtained
from a pharmacokinetic interaction study between simvastatin and
amlodipine; and (ii) to propose the optimal dose of simvastatin
needed to reduce the risk of an adverse drug reaction when the two
drugs are given together.
Materials and Methods
Pharamcokinetic data: The pharmacokinetic data were
obtained from a randomized, open-label, cross-over study con-
ducted in healthy Korean male volunteers in 2009 to investigate the
pharmacokinetics and drug interactions between simvastatin and
amlodipine.
The subjects were given a Zocor tablet 40mg (MSD Co., Ltd.;
simvastatin 40mg) only (single-administration) or a Zocor tablet
40mg and a Norvasc tablet 10mg (Pﬁzer Co., Ltd.; amlodipine
10mg) concomitantly (co-administration), each formulation given
q.d. for nine consecutive days, with a 14-day washout period. Blood
samples were collected on Day 9 before and 0.5, 1, 1.5, 2, 2.5,
3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 144, and 216 h after dosing for
co-administration or only up to 24 h for single-administration.
The study was approved by the Institutional Review Board
of Yonsei University Severance Hospital (Seoul, Korea) and
performed in accordance with the Declaration of Helsinki.
Sample assay: Plasma concentrations were quantiﬁed by LC-
MS/MS using the Agilent 1200 system (Agilent, Santa Clara, CA)
for HPLC and the 4000QTAP/API3200 system (Applied Bio-
systems/MDS SCIEX, Foster City, CA) for MS/MS. Detection was
achieved using MRM mode of positive electrospray ionization
(ESI+).
Each concentration of simvastatin, simvastatin acid and
amlodipine was determined by spiking 0.5mL of plasma with
lovastatin 15 µL, lovastatin acid 15µL, and nimodipine 50 µL
respectively as an internal standard, and was extracted by protein
precipitation. They were detected by mass spectrometry,9–12)
operating under the following conditions of mass transitions:
419¼285m/z for simvastatin, 437¼303m/z for simvastatin acid,
405¼199m/z for lovastatin, 423¼285m/z for lovastatin acid,
409¼238m/z for amlodipine, and 419¼343m/z for nimodipine.
The lower limit of quantiﬁcation (LLOQ) was 0.1 ng/mL for
simvastatin and simvastatin acid and 0.5 ng/mL for amlodipine,
with assay signal-to-noise (S/N) ratio >10.
The calibration curves were linear over the range of 0.2–
50 ng/mL, 0.1–25 ng/mL, and 0.2–20 ng/mL for simvastatin,
simvastatin acid, and amlodipine, respectively. They were devel-
oped using the following criteria: (1) the mean value should be
within «15% of the theoretical value (2) the precision should not
exceed 15% in coefﬁcient of variation and (3) the correlation
coefﬁcient should be greater than 0.95.
Population analysis: Population analysis was performed
using NONMEM (Version 7.2, ICON, Hanover, MD) and the First
Order Conditional Estimation method with interaction (FOCE
INTER) was used to ﬁt the model.13) PsN version 3.4.2 and Xpose
implemented in R was used in processing NONMEM 7 outputs.14,15)
Model selection was guided by the plausibility and precision of
parameter estimates, Akaike Information Criterion (AIC), as well
as goodness-of-ﬁt plots of observed concentrations versus time and
conditional weighted residuals (CWRES) versus time.
Model development: Assuming that amlodipine concentra-
tions are not inﬂuenced by simvastatin when the two drugs are co-
administered, the model development was conducted by ﬁrst
developing a model for amlodipine and then developing a model
for simvastatin and simvastatin acid, with the amlodipine model
parameters being ﬁxed at their post hoc estimates obtained at the
previous step. In each step, the effects of CYP3A4/5 polymor-
phisms and covariates on the plasma concentrations of simvastatin,
simvastatin acid and amlodipine were also explored. In developing
the interaction model, simvastatin and simvastatin acid data were
modelled simultaneously.
Model for amlodipine
The model for amlodipine was developed using amlodipine data
only. Assuming ﬁrst-order absorption, compartment models were
tested up to a 3-compartment model, and inﬂuences of CYP3A4/5
polymorphisms and covariates were examined.
Model for simvastatin and simvastatin acid
Basic model: Simvastatin absorption kinetics were modeled
by assessing various types of absorption processes including
a single absorption process such as ﬁrst-order absorption and
Weibull absorption and a multiple absorption process such as
simultaneous ﬁrst- and zero-order absorption, sequential zero- and
ﬁrst-order absorption, and a series of transit compartment absorp-
tions followed by ﬁrst-order absorption.16) Disposition kinetics of
simvastatin and simvastatin acid were modeled by assessing a one-,
a two- and a three-compartment model. For elimination kinetics,
simvastatin clearance was assumed to be the sum of the hepatic
clearance mediated by CYP3A4/5 and the conversion clearance
from simvastatin to simvastatin acid mediated by esterase,
paraoxonases, and non-enzymatic hydrolysis.
For inter-individual random effects, a proportional error model
was used, and for intra-individual random effects, a combined error
model was used to assess the relative contributions of additive
and proportional error components. Random effect associated with
crossover design was dealt with by including the inter-occasional
variability (IOV) into the model.
Model for interaction with amlodipine: It was assumed that
the interaction with amlodipine through CYP3A4/5 can occur in
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both intestinal walls and hepatocytes. For the former, simvastatin
bioavailability of co-administration was assumed to increase by a
constant fraction due to the inhibited activity of CYP3A4/5 present
on intestine walls, by the following relationship:
FSINGLE ¼ FR FCO ð1Þ
where FSINGLE and FCO denote simvastatin bioavailability of
single- and co-administrations, respectively, with FR < 1.
For the latter, the hepatic clearance of simvastatin and
simvastatin acid was assumed to be inhibited by the decreased
activity of CYP3A4/5 present in liver cells. In particular, the
activity of CYP3A4/5 in liver cells was assumed to be inhibited
associated with the plasma concentration of amlodipine as below:
INHCLP ¼ CLP  1 CP
KI þ CP
 
for simvastatin (2a)
INHCLM ¼ CLM  1 CP
KI þ CP
 
for simvastatin acid
(2b)
where CLP and CLM are the clearances of the parent drug and
the metabolite of simvastatin, INHCLP and INHCLM are their
respective inhibited clearances, CP is amlodipine plasma con-
centration, and KI is the inhibition constant, representing the
amlodipine concentration at 50% of maximum inhibition.
Model for inﬂuence by CYP polymorphisms: A mixture model
was used as below to describe the potential polymorphism of
CYP3A4/5 activities in simvastatin and simvastatin acid. This
genetic polymorphism is expected to produce two subgroups of
extensive (EM) and poor metabolizers (PM), with the different
bioavailabilities due to different activity levels of CYP3A/5
enzymes present on the intestinal wall and with the different
hepatic clearances due to different activity levels of CYP3A/5
enzymes present in liver cells. The difference in simvastatin
bioavailability between the two subgroups was modeled as
BAEM ¼ BA,EM  expðBA,EM Þ
1þ BA,EM  expðBA,EM Þ (3a)
BAPM ¼ 1 (3b)
PROEM ¼ PRO,EM (3c)
PROPM ¼ 1 PROEM (3d)
where BA;EM and BA;EM are ﬁxed and random effects, respec-
tively, for the bioavailability model for the EM subgroup with 0 <
BAEM < 1, and PROEM is the proportion of the subjects belonging
to the EM group. BAPM was ﬁxed to 1 to assume that the CYP3A4/
5 activity in intestinal walls for the PM group was at its minimal
level as compared to that for the EM group.
The difference in the hepatic clearance of the parent drug of
simvastatin between the two subgroups was modeled as follows:
CLPEM ¼ CLP,EM  expðCLPÞ (4a)
CLPPM ¼ CLP,PM  expðCLPÞ (4b)
where CLP;EM and CLP;PM are ﬁxed effects for the hepatic
clearance model for the EM and PM subgroups, respectively, and
CLP is the random effect.
The difference in the hepatic clearances of the metabolite of
simvastatin between the two subgroups was similarly modeled as
follows:
CLMEM ¼ CLM,EM  expðCLM Þ (4c)
CLMPM ¼ CLM,PM  expðCLM Þ (4d)
Model for covariate effects: As a ﬁnal step in the model
development, covariate analysis was undertaken to examine if
there were any signiﬁcant relationships between model parameters
and the following demographic factors: age, weight, height, sex,
smoking status, and alcohol consumption.
Stepwise covariate modeling (SCM) using PsN was performed at
signiﬁcance levels of p < 0.05 for forward selection and p < 0.001
for backward elimination. Here, due to the tremendous computa-
tional time required for covariate selection with the original
simultaneous model developed, without loss of generality, the
selection procedure was conducted separately for each sub-model in
a sequential manner in the following order: sub-model for
simvastatin for single-administration, sub-model for simvastatin
acid for single-administration, sub-model for simvastatin for co-
administration, and lastly the sub-model for simvastatin acid for co-
administration.
Model evaluation: The ﬁnal model was evaluated using a
visual predictive check (VPC) given 1,000 datasets simulated from
the ﬁnal model. Speciﬁcally, the percent of observed concen-
trations falling outside the 90% prediction interval, deﬁned by the
range between the 5th and 95th percentiles, was assessed for each
drug component.
Determination of an optimal simvastatin dose: Next, the
typical parameter estimates obtained from the ﬁnal model were
used to predict an optimal simvastatin dose to minimize the
increase in the steady-state concentrations of simvastatin and
simvastatin acid for a co-administration with amlodipine, relative
to a single-administration of simvastatin 40mg only. The search for
an optimal dose of simvastatin was made for a range of 2–50mg,
with a search interval of 2mg. The optimal simvastatin dose D* to
be co-administered with amlodipine was deﬁned as the dose that
minimizes the absolute relative error (ERR, %) as given below,
with i = 1 for simvastatin and i = 2 for simvastatin acid:
ERR ¼ ðERR1 þ ERR2Þ=2 (5a)
ERRi ¼ absðCmaxCi  CmaxSiÞ=CmaxSi  100; i ¼ 1; 2 (5b)
where CmaxCi is the typical steady-state Cmax of simvastatin (i = 1)
or simvastatin acid (i = 2) predicted for a co-administration of
simvastatin dose D and amlodipine 10mg for nine days, and
CmaxSi is the typical steady-state Cmax of simvastatin (i = 1) or
simvastatin acid (i = 2) predicted for a single-administration of
simvastatin 40 mg for nine days.
Results
Pharmacokinetic data: A total of 48 subjects were enrolled
and 44 completed the study. Their demographic data, consisting
of age, weight, and height as continuous covariates, and gender,
smoking status and alcohol consumption as dichotomous cova-
riates, are presented in Table 1.
According to preliminary analyses with a non-compartmental
method, our data showed in the case of co-administrating
simvastatin with amlodipine 1.8- and 1.9-fold increase for
simvastatin and 1.9- and 2.3-fold increase for simvastatin acid in
AUC and Cmax, respectively, as compared to a single administration
of simvastatin (not shown). These preliminary results provided
sufﬁcient justiﬁcation for using our data to develop an interaction
model between the two drugs.
Model development:
Model for amlodipine
Amlodipine data were best described by a two-compartment
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model with ﬁrst-order absorption. AIC values were 1,538 for the
one-compartment model and 1,504 for the two-compartment
model, with the estimation step not running successfully for a
three-compartment model. The pharmacokinetic parameters for
amlodipine estimated from the selected model are listed in
Table 2a. Relative standard errors of model parameters were
all below 30%. Age and weight were found to have a signiﬁcant
inﬂuence on clearance and peripheral volume of distribution (p <
0.001). Unlike the previous work,7) no signiﬁcant genetic dif-
ference was found when a mixture model was implemented. A
goodness of ﬁt for the selected model is drawn in Figure 1a,
showing no trend in the distribution of residuals.
Model for simvastatin and simvastatin acid
Basic model: To select a model for absorption kinetics,
simvastatin data from single-administration were analyzed prelimi-
narily using a one-compartment model for disposition kinetics.
The resulting AIC values were 122.8 for ﬁrst-order absorption,
89.8 for Weibull absorption, ¹45.2 for simultaneous ﬁrst- and zero-
order absorption, ¹43.2 for sequential zero- and ﬁrst-order absorp-
tion, and 323.6 for a series of transit compartment absorptions
followed by ﬁrst-order absorption. Although Weibull and multiple
absorption models gave smaller AIC values, ﬁrst-order absorption
was selected because the other types of absorption gave numerical
difﬁculties in the rest of the model building process.
Next, to select a model for disposition kinetics given ﬁrst-order
absorption, simvastatin data were re-analyzed and found to be best
described by a two-compartment model, yielding a smaller AIC
value than a one-compartment model (129.3 versus 132.8). A
three-compartment model was not taken into account because the
estimation step did not run successfully.
Then, conditioned on absorption and disposition parameter
estimates of simvastatin obtained at the previous steps, disposition
kinetics for simvastatin acid were characterized and found to be
best described by a one-compartment model. Here, because the
metabolite clearance and its distribution volume were not sepa-
rately identiﬁable unless the metabolite is administered alone or the
metabolic fraction is known, the volume of distribution of the
metabolite was ﬁxed to that of the parent drug.17)
Finally, simvastatin and simvastatin acid data were modeled
simultaneously, based on the basic model for simvastatin and
simvastatin acid consisting of a two-compartment model with ﬁrst-
order absorption for simvastatin, linked to a one-compartment
model for simvastatin acid. In modelling random effects, corre-
lations between model parameters were assumed to be zero because
otherwise the estimation procedure did not run successfully.
Model for interaction with amlodipine: As described in the
Methods section, when the relative bioavailability of simvastatin
for single-administration was represented as a fraction of that for
co-administration, it was estimated to be 0.68. This was equivalent
to saying that the relative bioavailability of simvastatin for co-
administration is about 1.46 times higher than that for single-
administration.
The inﬂuence of interaction with amlodipine on hepatic clear-
ance of simvastatin and simvastatin acid was estimated to reach
50% of its maximum level at an amlodipine concentration of
92.8 ng/mL.
Model for inﬂuence by CYP polymorphisms: A mixture model
to account for potential genetic variation of CYP3A5 activities
in simvastatin metabolism was tested in three subgroups. Our
results estimated the existence of two subgroups, with about 80%
belonging to the EM and 20% to the PM group. The relative
bioavailability of the EM group was estimated to be about 19% of
that of the PM group.
As compared to the PM group, the CYP3A4/5 mediated
hepatic clearance of the EM group was estimated to be 22% for
simvastatin (130.5 versus 604.1 L/h), and 61% for simvastatin acid
Table 1. Summary of demographic data for 48 healthy Korean male
subjects
Continuous Median Range
Age (years) 24 22–50
Weight (kg) 69.85 52.9–87.1
Height (cm) 174.4 162–186.3
Categorical
Gender (Male/Female) 48/0 —
Smoking (Yes/No) 29/19 —
Alcohol (Yes/No) 20/28 —
Xanthine (Yes/No) 19/29 —
Fig. 1. Model evaluation for amlodipine
(a) A goodness of ﬁt plot for the selected amlodipine model where AMLCO
denotes the amlodipine concentration under co-administration (=simvastatin
40mg and amlodipine 10mg given together q.d. for 9 days), and CWRES and
Prediction denote the conditional weighted residual and the model prediction,
respectively. (b) Visual predictive check results for the amlodipine model
obtained using 1,000 datasets simulated the ﬁnal model, where dotted lines
represent the 90% prediction interval and the solid line the median.
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(73.06 versus 120.6 L/h), equivalent to saying that the CYP3A4/5
mediated hepatic clearance of the PM group is about 4.63 and
1.65 times higher than that of simvastatin and simvastatin acid,
respectively.
Model for covariate effects: For covariate selection, no covariate
was found to be signiﬁcant. Although age was found to have a
signiﬁcant effect on clearance, it did not reach the signiﬁcance
level of p < 0.001 in the backward deletion and was excluded.
Parameter estimates for the ﬁnal model for simvastatin and
simvastatin acid are listed in Table 2b. The coefﬁcient of variation
for random effects was >50% in the inter-individual variability of
CLP and KI, and the inter-occasional variability of Q. For KA, V3,
and Q of amlodipine, the inter-individual random effect was not
considered because they gave relative standard errors larger than
50%. For CLC, the inter-individual random effect was not included
in the model because the run did not converge when it was
included. CWRES versus prediction plots are given in Figure 2a,
indicating a good agreement between the ﬁnal model and the data.
The ﬁnal model structure for simvastatin, simvastatin acid and
amlodipine is illustrated in Figure 3.
Table 2. Parameter estimates of the ﬁnal model
(a) Amlodipine (AML)
Parameter Covariate model ª (RSE%) ½ (CV %) (RSE%) p-value
KA (h¹1) KA = ªKA ªKA = 0.2083 (7.6%)
V2 (L) V2 = ªV20exp(©V2) ªV2 = 1,048 (8.5%) ½V2 = 32.7% (22.7%)
CL (L/h) CL = ªCL0{1 + ªCL AGE0(AGE ¹ 24.0)}0exp(©CL) ªCL = 32.38 (3.6%) ½CL = 22.6% (17.4%)
ªCL AGE = ¹0.01995 (10.1%) < 0.001
V3(L) V3 = ªV30{1 + ªV3 WT0(WT ¹ 69.8)} ªV3 = 969.7 (7.3%)
ªV3 WT = 0.01587 (31.4%) < 0.001
Q (L/h) Q = ªQ ªQ = 80.85 (9.2%)
Residual CP = ĈP0(1 + ¾pro) + ¾add ·pro = 11.7% (11.0%)
·add = 0.089 (19.7%)
KA, ﬁrst-order absorption rate constant; V2, central volume of distribution; CL, hepatic clearance; V3, peripheral volume of distribution; Q, intercompartmental
clearance; ½V2, inter-individual variability of V2; ½CL, inter-individual variability of CL; ·pro, proportional component of residual variability; ·add, additive component
of residual variability; AGE, age (years); WT, weight (kg).
RSE, relative standard error (=standard error/estimated value).
½V2, ½CL, and ·pro are in the unit of coefﬁcient of variation (CV).
(b) Simvastatin (SV) and simvastatin acid (SVA)
Parameter Covariate model ª (RSE%) ½ (CV %) (RSE%)
Simvastatin (SV)
KA (h¹1) KA = ªKA0exp(©KA) ªK12 = 0.3505 (6.1%) ½KA = 30.1% (34.1%)
V2 (L) V2 = ªV20exp(©V2 + ¬V2,j) ªV2 = 200.3 (25.0%) ½V2 = 29.7% (75.9%)
³V2 = 45.8% (29.1%)
CLP (L/h) CLP = ªCLP0exp(©CLP) ªCLP(EM) = 130.5 (27.7%) ½CLP = 62.3% (43.8%)
ªCLP(PM) = 604.1 (26.4%)
CLC (L/h) CLC = ªCLC ªCLC = 123.8 (26.2%)
V3 (L) V3 = ªV3 ªV3 = 2,322 (26.0%)
Q (L/h) Q = ªQ0exp(¬Q,j) ªQ = 62.06 (26.0%) ³Q = 155.2% (32.1%)
F FSINGLE = FR0FCO
FCO = BA ªBA,E = 0.2334 (17.3%)
BA BAEM = ªBA,EM0exp(©BA,EM)/{1 + ªBA,EM0exp(©BA,EM)} ½BA,EM = 44.9% (35.9%)
BAPM = 1 ªFR = 2.152 (24.9%)
FR FR = ªFR/(1 + ªFR)
KI (ng/mL) KI = ªKI0exp(©KI) ªKI = 92.83 (32.2%) ½KI = 159.8% (28.0%)
PRO PROEM = ªPRO,EM
ªPRO,EM = 0.7965 (10.1%)PROPM = 1 ¹ PROEM
Residual CPSV = ĈPSV0(1 + ¾SV,pro) + ¾SV,add ·SV,pro = 52.8% (7.9%)
·SV,add = 0.0035 (23.6%)
Simvastatin acid (SVA)
CLM (L/h) CLM = ªCLM0exp(©CLM) ªCLM(EM) = 73.06 (25.3%) ½CLM = 38.5% (32.7%)
ªCLM(PM) = 120.6 (24.9%)
V4 (L) V4 = V2
Residual CPSVA = ĈPSVA0(1+¾SVA,pro) + ¾SVA,add ·SVA,pro = 36.8% (12.6%)
·SVA,add = 0.012 (50.6%)
KA, ﬁrst-order absorption rate constant; V2, central volume of distribution of parent drug; V3, peripheral volume of distribution of parent drug; CLP, hepatic clearance
of parent drug; CLC, conversion clearance of parent drug; Q, inter-compartmental clearance of parent drug; F, bioavailability difference with formulation;
BA, bioavailability difference with subgroup; FR, bioavailability ratio of single- to coadministration; KI, inhibition constant; PRO, proportion of the subjects belonging
to each subgroup; CLM, hepatic clearance of metabolite; V4, volume of distribution of metabolite; ½KA, inter-individual variability of KA; ½V2, inter-individual
variability of V2; ½CLP, inter-individual variability of CLP; ½BA, inter-individual variability of BA; ½KI, inter-individual variability of KI; ½CLM, inter-individual
variability of CLM; ¬V2,j, inter-occasional random effect of V2 for single- (j = 1) and co-administration (j = 2); ³V2, variability of ¬V2,j; ¬Q,j, inter-occasional random
effect of Q for single- (j = 1) and co-administration (j = 2); ³Q, variability of ¬Q,j; ·pro, proportional component of residual variability; ·add, additive component of
residual variability.
SINGLE, single-administration (=simvastatin administered only); CO, co-administration (=simvastatin and amlodipine administered concomitantly); PM, poor
metabolizers; EM, extensive metabolizers.
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Model evaluation: VPC results obtained from 1,000
datasets simulating the ﬁnal model are depicted in Figure 1b for
amlodipine and Figure 2b for simvastatin and simvastatin acid.
For the model for amlodipine, 6.4% of observations fell outside the
90% prediction interval, and for the model for simvastatin and
simvastatin acid, 4.4% and 1.8% of observations for co-admin-
istration and 1.0% and 1.3% of observations for single-admin-
istration fell outside their respective 90% prediction interval,
Fig. 2. Model evaluation for simvastatin and simvastatin acid
(a) Goodness of ﬁt plots for the selected model for simvastatin and simvastatin acid concentration where SVSINGLE and SVASINGLE denote simvastatin and simvastatin
acid for single-administration (=simvastatin 40mg given alone q.d. for 9 days), respectively, SVCO and SVACO denote simvastatin and simvastatin acid for co-
administration (=simvastatin 40mg and amlodipine 10mg given together q.d. for 9 days), respectively, and CWRES and Prediction denote the conditional weighted
residual and the model prediction, respectively. (b) Visual predictive check results for the model for simvastatin and simvastatin acid obtained using 1,000 datasets
simulated from the ﬁnal model, where dotted lines represent the 90% prediction interval and the solid line the median.
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indicating the adequacy of the developed model.
Determination of an optimal simvastatin dose: The dose
optimization results using the typical parameter estimates obtained
from the ﬁnal model are summarized in Table 3 and the predicted
concentrations of simvastatin and simvastatin acid given the
optimal dose are shown in Figure 4. The optimal simvastatin dose
D* that minimizes the concentration increase when co-adminis-
tered q.d. with amlodipine 10mg was estimated to be 24mg for
both the PM and EM groups. Note in the table that CmaxS becomes
higher in the EM group.
Fig. 3. The ﬁnal model structure for simvastatin, simvastatin acid and amlodipine
Table 3. The optimal dosage regimen results for simvastatin that minimize
the interaction with amlodipine in co-administration
CmaxS (ng/mL)
Dose
(mg)
CmaxC1
(ng/mL)
CmaxC2
(ng/mL)
ERR1
(%)
ERR2
(%)
ERR
(%)
EM CmaxS1 = 3.81 24 3.49 3.77 8.4 0.5 4.4
CmaxS2 = 3.79 40 5.81 6.28 52.7 65.9 59.3
PM CmaxS1 = 9.41 24 8.82 6.13 6.3 3.6 4.9
CmaxS2 = 5.92 40 14.70 10.22 56.2 72.6 64.4
The result for a simvastatin dose of 40mg was listed together for comparison.
For symbols, see text.
Fig. 4. Concentrations of simvastatin (SV) (left panels) and simvastatin acid (SVA) (right panels) simulated from the ﬁnal model for a daily dose of
simvastatin 24mg co-administered with amlodipine 10mg for nine days (solid line), superimposed on predicted concentrations for single-administration of
simvastatin 40mg only (dashed line), obtained in EM (upper panels) and PM groups (lower panels)
Predicted concentrations for co-administration of simvastatin 40mg with amlodipine 10mg were also plotted for comparison (dotted line).
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Discussion
In this study, we developed a model-based approach to charac-
terize the drug-drug interaction between simvastatin and amlodipine
and how it can be used in selecting an optimal simvastatin dose that
can avoid an unwanted increase in simvastatin plasma concen-
tration, thereby minimizing the risk of adverse drug reactions while
maintaining drug efﬁcacy.
The selected interaction model was described using a two-
compartment model with ﬁrst-order absorption for simvastatin,
linked to a one-compartment model for simvastatin acid, given a
two-compartment model with ﬁrst-order absorption for amlodipine.
The important model components characterizing the drug-
drug interaction between simvastatin and amlodipine were (1)
the inhibitory effect of amlodipine on simvastatin metabolism
modeled as a function of amlodipine plasma concentration; and
(2) CYP3A4/5 polymorphisms in simvastatin bioavailability and
hepatic clearance implemented by the mixture model.
Simvastatin has been reported to have a moderate binding
afﬁnity to CYP3A4/5 and might be more easily detached by
other substrates with a higher binding afﬁnity such as amlodipine.
Thus, during the modeling process, we assumed that amlodipine
competitively inhibited the metabolism of simvastatin and
simvastatin acid, but not vice versa. This was experimentally
conﬁrmed in our separate trial where for the same subjects who
participated in this study amlodipine 10mg was given alone
q.d.; resulting AUC and Cmax of amlodipine were found to be
not signiﬁcantly different from those for co-administration (not
shown). Thus, the amlodipine data were modeled separately and
the post hoc parameter estimates of amlodipine were used in the
parent-metabolite model of simvastatin in a sequential manner.
Given the reversible interconversion between simvastatin and
simvastatin acid, we initially tried including in the model the rate
constants of both the forward conversion of simvastatin to
simvastatin acid and the backward conversion of simvastatin acid
to simvastatin. However, the model did not successfully converge
when the two conversion rate constants were included because
there was strong correlation between the parent and metabolite
concentrations and the two conversion rate constants could not be
estimated separately.
For the inhibitory effect of amlodipine on simvastatin metabo-
lism, the simvastatin bioavailability for co-administration increased
1.46-fold, compared to that of single-administration. This increase
was associated with reduced activity of CYP3A4/5 located on
the intestine, which is a major site responsible for low oral
bioavailability when the activity of CYP enzymes is inhibited.18)
In our analysis, the inhibition rate constant KI, which was estimated
to be 92.8 ng/mL, was modeled to be common to simvastatin and
simvastatin acid because it was legitimate to assume that the
inhibition mechanism by amlodipine concentration would not differ
between the parent drug and metabolite. This means a 13% decrease
in the clearance of both simvastatin and simvastatin acid when
evaluated at the typical Cmax of amlodipine, which was predicted to
be 14 ng/mL for the daily amlodipine dose of 10mg.
In the mixture model, the metabolic clearance of simvastatin
and simvastatin acid was allowed to vary between the EM and
PM groups because both moieties are metabolized by CYP3A4/5,
which has potential genetic polymorphisms. Interestingly, as
reported in Table 2, the result was that the hepatic clearance of
the EM subgroup was lower than that of the PM subgroup in both
simvastatin and simvastatin acid. The reason would be that because
for simvastatin the ﬁrst-pass metabolism takes place largely in the
gut wall, the amount of simvastatin entering into the systemic
circulation becomes much lower in the EM group than in the
PM group, leading to the reduced amount of simvastatin available
in hepatic metabolism in the EM group. As a result, the hepatic
clearance of simvastatin in the EM group could become lower than
in the PM group. Further, as the blood amount of simvastatin acid
would be smaller in the EM group due to the smaller amount
of simvastatin available for its conversion to simvastatin acid, the
resulting hepatic clearance of simvastatin acid in the EM group
could become lower than in the PM group. This was also con-
ﬁrmed by a noncompartmental analysis of the terminal half-life,
which was found to be longer in the EM group (not shown),
supporting the lower clearance of this subgroup obtained from the
modeling result. Table 2 also reports that the between-group
difference in simvastatin acid clearance was smaller than for
simvastatin clearance (1.65 times versus 4.63 times). A possible
explanation for this is that the metabolite is a byproduct of the
metabolism of the parent drug, and a large portion of between-
group differences in simvastatin acid concentration was inherited
from the between-group difference in simvastatin concentration,
and thus only a small portion is accounted for by the additional
difference in simvastatin acid concentration. In modeling the inter-
individual variability, we assumed it was the same for the 2 sub-
groups [Eq. (4)], because the estimation step did not run
successfully when it was allowed to vary.
Elevated simvastatin concentrations occurring from drug-drug
interactions can cause adverse reactions such as rhabdomyolysis,
which can be a serious problem, particularly in the PM group. Such
drug interactions can be avoided by adjusting the dosage and/or
dosing time.19) According to Table 2a, however, amlodipine half-
life was estimated to be as long as 22 h, indicating adjusting dosing
time would be almost unrealistic. Therefore, as an alternative,
adjusting the simvastatin dose was suggested in this work based on
the model developed. Our results showed that, in both the EM
and PM groups, simvastatin 24mg was an optimal dose in a co-
administration with amlodipine 10mg that can minimize the
concentration increase in simvastatin and simvastatin acid due to
drug-drug interaction with amlodipine, thereby achieving a
concentration proﬁle similar to that for single-administration of
simvastatin 40mg only. In other words, when simvastatin 40mg
is co-administered with amlodipine 10mg, we suggest that a
40% dose reduction of simvastatin is needed to avoid drug-drug
interactions.
Although no covariate was found to be signiﬁcant in our study,
age has been reported to be inﬂuential on clearance in studies with
larger populations.20)
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